Hexarelin

Approved source records

1. Growth hormone-releasing peptides.

   DOI: 10.1530/eje.0.1360445

   Source identity and connection checked by Codex (AI).

2. Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.

   DOI: 10.1007/s12020-015-0531-z

   Source identity and connection checked by Codex (AI).

3. Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.

   Bo Jiang; Mo Wang; Xue Li; Pengwei Ren; Guangxin Li; Yuqi Wang; Lei Wang; Xuan Li; Dong Yang; Lingfeng Qin; Shijie Xin · Microvascular research · 2022

   DOI: 10.1016/j.mvr.2021.104280PMID: 34856183

4. Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats.

   Tayfun Baser; Ercan Ozdemir; Ahmet Kemal Filiz; Ahmet Sevki Taskiran; Sinan Gursoy · Canadian journal of physiology and pharmacology · 2021

   DOI: 10.1139/cjpp-2020-0218PMID: 32893668

5. Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity.

   Ramona Meanti; Laura Rizzi; Elena Bresciani; Laura Molteni; Vittorio Locatelli; Silvia Coco; Robert John Omeljaniuk; Antonio Torsello · Pharmaceuticals (Basel, Switzerland) · 2021

   DOI: 10.1016/j.pneurobio.2005.02.004PMID: 34066741

6. Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury.

   Vanessa Zambelli; Laura Rizzi; Paolo Delvecchio; Elena Bresciani; Emanuele Rezoagli; Laura Molteni; Ramona Meanti; Maria Serena Cuttin; Giorgio Bovo; Silvia Coco; Robert J Omeljaniuk; Vittorio Locatelli · Drug target insights · 2021

   DOI: 10.1164/rccm.201306-1141WSPMID: 34871336

7. Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models.

   Mark T Waddingham; Hirotsugu Tsuchimochi; Takashi Sonobe; Ryotaro Asano; Huiling Jin; Connie P C Ow; Daryl O Schwenke; Rajesh Katare; Kohki Aoyama; Keiji Umetani; Masato Hoshino; Kentaro Uesugi · Frontiers in physiology · 2021

   DOI: 10.1007/s00424-004-1243-zPMID: 35126171

8. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.

   Jamshaid Ahmad; Saima Ikram; Fawad Ahmad; Irshad Ur Rehman; Maryam Mushtaq · Heliyon · 2020

   DOI: 10.1016/j.heliyon.2020.e04502PMID: 32754651

9. Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE-/- mice.

   Xiu-Li Cheng; Fan Ding; De-Ping Wang; Lan Zhou; Ji-Min Cao · Peptides · 2019

   DOI: 10.1016/j.peptides.2019.170122PMID: 31386895

10. Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy.

    E Agbo; M-X Li; Y-Q Wang; R-O Saahene; J Massaro; G-Z Tian · Die Pharmazie · 2019

    DOI: 10.1691/ph.2019.9324PMID: 31526442

11. Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats.

    Elvis Agbo; Donhai Liu; Meixiu Li; Roland Osei Saahene; Liqiang Chen; Lunpeng Zhao; Yiquan Wang; Guozhong Tian · Turkish journal of medical sciences · 2019

    DOI: 10.3906/sag-1812-49PMID: 31091855

12. Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats.

    Xinli Zhang; Linbing Qu; Ling Chen; Chen Chen · Physiological reports · 2018

    DOI: 10.14814/phy2.13612PMID: 29446246

13. The CD36-PPARγ Pathway in Metabolic Disorders.

    Loïze Maréchal; Maximilien Laviolette; Amélie Rodrigue-Way; Baly Sow; Michèle Brochu; Véronique Caron; André Tremblay · International journal of molecular sciences · 2018

    DOI: 10.1172/JCI27794PMID: 29883404

14. The Safety and Efficacy of Growth Hormone Secretagogues.

    John T Sigalos; Alexander W Pastuszak · Sexual medicine reviews · 2018

    DOI: 10.1016/j.sxmr.2017.02.004PMID: 28400207

15. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway.

    Jiannan Huang; Yi Li; Juan Zhang; Yusheng Liu; Qinghua Lu · International heart journal · 2017

    DOI: 10.1536/ihj.16-241PMID: 28321024

16. The cardiovascular action of hexarelin.

    Yuanjie Mao; Takeshi Tokudome; Ichiro Kishimoto · Journal of geriatric cardiology : JGC · 2014

    DOI: 10.11909/j.issn.1671-5411.2014.03.007PMID: 25278975

17. We are ageing.

    Genovefa D Kolovou; Vana Kolovou; Sophie Mavrogeni · BioMed research international · 2014

    DOI: 10.1155/2014/808307PMID: 25045704

18. New active series of growth hormone secretagogues.

    Vincent Guerlavais; Damien Boeglin; Delphine Mousseaux; Catherine Oiry; Annie Heitz; Romano Deghenghi; Vittorio Locatelli; Antonio Torsello; Corrado Ghé; Filomena Catapano; Giampiero Muccioli; Jean-Claude Galleyrand · Journal of medicinal chemistry · 2003

    DOI: 10.1021/jm020985qPMID: 12646029

19. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation.

    I Pettersson; G Muccioli; R Granata; R Deghenghi; E Ghigo; C Ohlsson; J Isgaard · The Journal of endocrinology · 2002

    DOI: 10.1677/joe.0.1750201PMID: 12379504

20. Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death.

    N Filigheddu; A Fubini; G Baldanzi; S Cutrupi; C Ghè; F Catapano; F Broglio; A Bosia; M Papotti; G Muccioli; E Ghigo; R Deghenghi · Endocrine · 2001

    DOI: 10.1385/ENDO:14:1:113PMID: 11322493

21. Hexarelin--evaluation of factors influencing oral bioavailability and ways to improve absorption.

    C Westberg; K Benkestock; A Fatouros; M Svensson; B Sjöström · The Journal of pharmacy and pharmacology · 2001

    DOI: 10.1211/0022357011776540PMID: 11578108

22. Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats.

    M Roumi; S Marleau; P du Souich; T Maggi; R Deghenghi; H Ong · Drug metabolism and disposition: the biological fate of chemicals · 2000

    PMID: 10611139

23. Growth hormone in obesity.

    M Scacchi; A I Pincelli; F Cavagnini · International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 1999

    DOI: 10.1038/sj.ijo.0800807PMID: 10193871

24. Hexarelin as a test of pituitary reserve in patients with pituitary disease.

    M Korbonits; G Kaltsas; L A Perry; A B Grossman; J P Monson; G M Besser; P J Trainer · Clinical endocrinology · 1999

    DOI: 10.1046/j.1365-2265.1999.00828.xPMID: 10469018

25. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.

    A Rahim; P A O'Neill; S M Shalet · Clinical endocrinology · 1999

    DOI: 10.1046/j.1365-2265.1999.00609.xPMID: 10341859

26. Does desensitization to hexarelin occur?

    A Rahim; S M Shalet · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1998

    DOI: 10.1016/s1096-6374(98)80039-7PMID: 10990150

27. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.

    A F Massoud; P C Hindmarsh; C G Brook · The Journal of clinical endocrinology and metabolism · 1996

    DOI: 10.1210/jcem.81.12.8954038PMID: 8954038